IRCT20131125015536N8已完成未知
The study of the effect of nano-curcumin supplementation on biomarkers of endothelial function and inflammation in overweight or obese patients with Coronary Slow Flow Phenomenon
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 42
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 35 years 至 70 years（—）
- 性别
- All
入选标准
- •35 to 70 years old men and women
- •BMI range: 25 - 39.9
- •Angiographically diagnosed as coronary slow flow phenomenon by Corrected TIMI Frame Count (CTFC) method which is equivalent to 27 or higher for one or more coronary vessels.
- •Normal coronary vessels with coronary stenosis less than 40%
- •Left ventricular ejection fraction higher than 45%
- •Giving informed consent for participation in the study
排除标准
- •Premature menopause
- •addiction or alcohol consumption
- •Routine use of NSAIDs or antioxidants one month prior to study
- •Use of aphrodisiac medication within 9 months before study
- •Routine use of corticosteroids or immunosuppressants
- •Use of anticonvulsants
- •Taking antioxidant or omega3 supplements (more than 3 grams per day) at least twice a week within 3 months prior to study
- •Taking vitamin B12, folic acid or vitamin B6 supplements within one month before study
- •Being a professional athlete or execising regularly
- •Uncontrolled hypertension defined as diastolic blood pressure above 90 mmHg, systolic blood pressure above 140 mmHg.
- •Past medical history: hypothyroidism or hyperthyroidism
- •Chronic obstructive pulmonary diseases
- •Systemic diseases
- •Connective tissue diseases
- •Renal failure
- •Liver failure
- •Autoimmune diseases
- •Myocardial Infarction
- •Sever heart failure
- •Heart transplant
- •Revascularization procedure or PCI or CABG
- •Left ventricular dysfunction or echocardiographically diagnosed left ventricular hypertrophy
- •Cardiac conduction disturbances
- •Valvular heart disease
- •Atrial fibrillation
- •Cardiomyopathy
- •Congenital heart disease
- •Coronary artery disease
- •Hematologic disorders
研究者
相似试验
已完成
3 期
The effects of nano-curcumin on obstructive pulmonary disease patientsIRCT20191222045853N1Oroumia University of Medical Sciences60
尚未招募
3 期
Investigating the effect of nanocurcumin in psychotic methamphetamine usersPsychotic methamphetamine users.???????? ????? ? ?????? ???? ?? ???? ???? ?????????F10-F19IRCT20240208060938N1Kashan University of Medical Sciences50
招募中
3 期
The effect of Nanocurcumin on liver fibrosisiver fibrosis.IRCT20210427051098N2Yazd University of Medical Sciences50
已完成
2 期
Therapeutic Effects of Curcumin as Supplement on Metabolic SyndromeCondition 1: Hypertension. Condition 2: Hyperglyceridaemia. Condition 3: Prediabetic. Condition 4: low HDL-C.Secondary hypertension, unspecifiedPure hyperglyceridaemiaAbnormal glucose tolerance testHigh-density lipoprotein deficiencyIRCT2016021326530N1Vice – Chancellery of Research & Technology Affairs of Kermanshah University of Medical Sciences90
招募中
不适用
Assessment of the effect of nanocurcumin supplement in patients with COVID-19COVID-19.Coronavirus infection, unspecifiedU07.1IRCT20131125015536N13Tehran University of Medical Sciences48